Synta Pharmaceuticals Corp. (NASDAQ:SNTA) focus on treatment of cancer and in the preclinical-stage


The share prices of Synta Pharmaceuticals Corp. (NASDAQ:SNTA) had surged by 0.85 percent and currently trading at $4.73 per share. The shares of the company is trading with narrow fluctuations in intraday prices in the range of $4.64 to $4.79 per during the day. The shares Synta Pharmaceuticals Corp. (NASDAQ:SNTA) had a market capitalization of $327 Million. The stock opened at $4.76 per share. The share price does not make a change in the 52 week low value $3.76 per share and 52 week high value $11.88 per share.

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) is concentrated on developing commercializing and discovering drugs for the patients with and inflammatory diseases and cancer. This company is also said to be Biopharmaceutical Company. In the clinical trials two drug candidates were used for the treatment of cancer and in the preclinical-stage many drug candidates are developed.  Integrated discovery engine and chemical compound library are used internally for develop and discover drug candidates. A non-small cell lung cancer as docetaxel joined with Phase 2b/3 clinical trial these are initiated by the company on December 2011. In oncology there is one preclinical-stage program and two clinical-stage programs. The company concentrated on ganetespib program on 2011 and the company also concentrated on calcium modulator programs and elesclomol.

To increase Synta Pharmaceuticals Corp. (NASDAQ:SNTA)’s authorized shares of stock based on this the company filed a certificate of amendment with the Secretary of State. Second-line treatment for patients with advanced non-small cell lung adenocarcinoma is Hsp90 inhibitor ganetespib. There is a significant improvement in the treatment of ganetespib. The company had an institutional investor’s shareholdings as 41 percent. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) has been having a trading volume of 2.13 million. The company presently holds 69.13 million shares outstanding in the market.